This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

HIV Researchers Celebrate 20 Years Of Collaboration

KANSAS CITY, Mo., April 23, 2013 (GLOBE NEWSWIRE) -- The HIV Outpatient Study (HOPS), supported by Cerner's Infectious Disease Insights group, HIV clinic researchers, and the dedicated project team from the Centers for Disease Control and Prevention (CDC) will be celebrating its 20th Anniversary during the Annual HOPS Investigator meeting held in April in Tampa, Fla.

HOPS, one of the largest U.S. government-funded longitudinal cohort studies, follows HIV-infected patients to gain insights to improve prevention and treatment of HIV/AIDS. CDC initiated the study in 1993 to describe and monitor trends in demographics, symptoms, diagnoses, and treatments in a population of HIV-infected outpatients in nine clinics across the United States. HOPS researchers at these clinics gather clinical, immunologic and virologic data, as well as genotypic and phenotypic information through periodic reviews of medical records.

Through analysis of HOPS data, researchers have verified the impact of existing therapeutics, gained knowledge to inform new best practices in prevention and treatment and discovered new concerns warranting additional study. To date, researchers have shared HOPS study findings through 56 published manuscripts and 115 abstracts and presentations, thus enhancing the medical community's understanding of prolonged survival, the metabolic problems associated with combination antiretroviral therapy (cART), adherence to cART, and the occurrence of comorbidities.

"HOPS is a unique study that highlights the power of true collaboration," said Dr. Sam Bozzette, a Cerner executive and internationally-recognized HIV researcher who provides strategic oversight to Cerner's HOPS team. "HOPS is designed to encourage the exchange of ideas among the research stakeholders from the CDC and participating clinic sites and provides them with the flexibility and agility to explore concerns and ideas as they become apparent."

Dr. John T. Brooks, the medical epidemiologist in CDC's Division of HIV/AIDS Prevention who oversees the study, commented, "HOPS has been instrumental in highlighting the health challenges faced by persons living with HIV in the United States. He added, "Through analyses of data from more than 9,000 HIV-infected patients who volunteered to participate in this research from 1993 to date, we have been able to document new complications associated with chronic HIV disease such as cardiovascular and bone disorders. We also continue to demonstrate the value of cART and preventative strategies for extending and improving patients' lives."

Stock quotes in this article: CERN 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs